No Data
No Data
The Market Lifts Shanghai Medicilon Inc. (SHSE:688202) Shares 41% But It Can Do More
shanghai's three major leading industry mother funds have started, catalyzing CRO companies like shanghai medicilon inc. to embrace new opportunities for technological innovation.
Recently, Shanghai Guotou Leading Private Equity Fund Management Company officially launched the selection work for the sub-funds of the three leading industrial parent funds, aiming to enhance the development level of Shanghai's integrated circuits, biomedical, and ai industries, in order to promote the high-quality development of the Shanghai economy. As one of the economic centers of China, Shanghai, with biomedical as an important industry pillar, has nurtured many excellent research institutions and high-level pharmaceutical companies here. The scale of the Shanghai biomedical industry has grown from 103.46 billion yuan in 2008 to 600 billion yuan in 2020, with a compound annual growth rate of 15.8%.
Shanghai Medicilon Inc.'s (SHSE:688202) Market Cap Increased by CN¥767m, Insiders Receive a 46% Cut
Shanghai Medicilon Inc. (688202.SH): In August, the company did not repurchase shares.
On August 31, 2024, Medicilon Inc. (688202.SH) announced that it did not repurchase any shares in August 2024. As of August 31, 2024, the company has repurchased a total of 258,153 shares through the Shanghai Stock Exchange system, accounting for 0.1917% of the total share capital. The highest price at which the shares were repurchased was RMB 32.55 per share, and the lowest price was RMB 26.44 per share. The total amount paid was RMB 7,450,315.99 (excluding stamp duty, transaction fees, and other expenses).
Shanghai Medicilon Inc.: Half-year report for the year 2024.
Shanghai Medicilon Inc.: Summary of Half-Year Report in 2024.
No Data
No Data